How to Buy Spero Therapeutics Stock
Spero Therapeutics Inc
Spero Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Spero Therapeutics stock last closed at $0.73, up 0.97% from the previous day, and has decreased 47.9% in one year. It has overperformed other stocks in the Biotechnology industry by 0.29 percentage points. Spero Therapeutics stock is currently +44.95% from its 52-week low of $0.51, and -57.44% from its 52-week high of $1.72.
As of Apr 22, 2025, there are 55.9M SPRO shares outstanding. The market value of SPRO is $40.92M. In the last 24 hours, 97,664 SPRO shares were traded.
How to Buy Spero Therapeutics Stock
Not sure how to invest in Spero Therapeutics stock? Here's how.
- Decide where to buy Spero Therapeutics stock: You need to choose an online brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you determine where to buy Spero Therapeutics stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Choose your method of payment and add your details.
- Research Spero Therapeutics stock: The Spero Therapeutics ticker symbol is SPRO. Is Spero Therapeutics stock a good investment? Should you buy shares of SPRO? How do SPRO's underlying business fundamentals look? Do top analysts think Spero Therapeutics is a good buy? Why has SPRO's stock price moved recently? (Hint: Our stock analysis website can help you understand if SPRO is a good stock to buy).
- Execute your SPRO trade: Decide if you will purchase SPRO shares at the current market price or use a limit order to purchase SPRO stock at a particular price.
- Get the latest scoop on your investment in SPRO: Create a watchlist to monitor your new investment in Spero Therapeutics shares.
Step 1: Decide where to buy Spero Therapeutics stock
You need an online brokerage account in order to access the NASDAQ market and buy SPRO shares.
Our favorite brokerage: eToro
In our opinion, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world financial markets: From Technology to Healthcare, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen your brokerage, you need to fill out some personal info so you can invest in SPRO stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to start a new brokerage account.
- Send your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've finished signing up on one of the best stock trading apps, you need to deposit funds:
Check out the tutorial below to see the process of depositing money into your new investment account.
Step 4: Research Spero Therapeutics stock
After you have chosen the best place to buy Spero Therapeutics stock, it's absolutely critical to research their stock prior to buying, so you can comprehend the risk and upside.
Spero Therapeutics quick stats
Spero Therapeutics Due Diligence Checks
WallStreetZen was designed to help average investors perform more in-depth fundamental analysis in less time.
You can view all of the due diligence checks on SPRO's stock page.
Is SPRO stock properly valued?
Analysts use many financial metrics, analyses, models, and charts to gauge SPRO's true value.
Using relative valuations ratios:
- SPRO may be undervalued based on its P/B ratio of 0.89x, relative to Biotechnology industry P/B ratio of 4.16x
You can access additional valuation analysis on SPRO's stock here.
SPRO Financials at a glance
Positive Financial Indicators:
- SPRO has cash burn of 23444000. It has enough cash and short-term investments to cover this for at least one year.
- SPRO has $52.89M in cash and short term investments. This is enough to cover its annual cash burn of $23.44M.
- There are more short-term assets than short-term liabilities on the SPRO balance sheet.
- There are more short-term assets than long-term liabilities on the SPRO balance sheet.
Negative Financial Indicators:
- SPRO has a relatively high debt to equity ratio of 1.4.
- Total SPRO debt is higher than 5 years ago, relative to shareholder equity.
- SPRO profit margin has gone down from 22% to -142.9% in the past year.
Do Wall Street analysts think it's a good time to buy SPRO stock
Out of 2 Wall Street analysts who monitor SPRO, the consensus analyst rating on SPRO is a Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
You can dig deeper into what analysts are forecasting on the Spero Therapeutics stock forecast page.
Metrics for Advanced SPRO Traders
How are SPRO Revenues/Earnings doing?
Last year, SPRO revenue was $47.98M. During the past five year, SPRO's revenue has grown by 21.46% per year. This was slower than the Biotechnology industry average of 44.4%.
Dive into SPRO's earnings and revenue performance here.
Latest Insiders Trades at SPRO
Over the last 12 months, executives and large shareholders at SPRO have sold more shares than they have bought.
Timothy Keutzer, Chief Operating Officer of SPRO, was the latest SPRO insider to sell. They sold $3,099.72 worth of SPRO stock on Feb 5, 2025.
Dig into more about who owns SPRO shares here.
Does SPRO provide a stable income stream?
No, Spero Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about SPRO?
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Execute your SPRO trade
You have two primary order types:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly fine for most investors. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount limit, place a limit order.
Press the Open button and eToro will execute your order.
If you need additional help with buying stocks on eToro, watch the helpful video below:
Step 6: Get the latest scoop on your investment in SPRO
Now that you own some shares in SPRO, you'll want to keep up with your shares.
Add SPRO to a watchlist to see the latest developments about your SPRO stock.
SPRO Feed
How to Buy Stock in Spero Therapeutics
To summarize, here are the 6 steps you need to take to buy Spero Therapeutics stock right now:
- Decide where to buy Spero Therapeutics stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Research Spero Therapeutics stock
- Execute your SPRO trade
- Get the latest scoop on your investment in SPRO
If you are looking for a online brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to monitor your investment in Spero Therapeutics, create your watchlist below.
More "How To" Guides You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.